Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
format_facet:"Gedruckte Aufsätze"
journalStr:"Hepatology"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=format_facet%3A%22Gedruckte+Aufs%C3%A4tze%22&filter%5B%5D=journalStr%3A%22Hepatology%22&lookfor=%22ClinicalTrials.gov%22&type=JournalTitle
/vufind/Search/Results?filter%5B%5D=format_facet%3A%22Gedruckte+Aufs%C3%A4tze%22&filter%5B%5D=journalStr%3A%22Hepatology%22&lookfor=%22ClinicalTrials.gov%22&type=JournalTitle
Search /vufind/Search2/Results?filter%5B%5D=format_facet%3A%22Gedruckte+Aufs%C3%A4tze%22&filter%5B%5D=journalStr%3A%22Hepatology%22&lookfor=%22ClinicalTrials.gov%22&type=JournalTitle
PubPharm (4)
1
Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant diseaseThis study has been registered (registration number NCT00895596) in ClinicalTrials.gov (URL http://clinicaltrials.gov/ct2/show/NCT00895596?term=LB80380&rank=1).This study was supported by LG Life Sciences which also provided the drug LB80380. The data collection and data report were carried out by an independent data management company, Covance Pty Limited, Australia. The analysis and the writing of the manuscript were mainly performed by the first two authors as well as the corresponding author. The drug company employees read and commented on the manuscript, and gave their approval.Potential conflicts of interest: M. F. Y. and C. L. L. have received speakers' honoraria from LG Life Sciences. H. R. K. and C. R. K. are full-time employees of LG Life Sciences. J. K. is a former employee of LG Life Sciences.Correction added after online publication 20 January 2010: Dr. Kwang-
enthalten in:
Hepatology
| 2010
von
Griffiths, W.
|
Mayr, R.
|
McFarlane, I.
| +4
Wird geladen...
2
Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trialMembers of the LIDO Study Group are listed in the acknowledgments.ClinicalTrial.gov identifier number: NCT00492700.Conflict of interest: This was an investigator initiated trial and GlaxoSmithKline Pharmaceuticals had no direct or indirect involvement in the design of the trial, data collection or preparation, or submission of the article. GSK provided rosiglitazone for this trial and partly funded the trial. None of the authors has a personal conflict of interest with the manufacturers of any of the marketed glitazones. V.R. is a consultant to Astellas, Axcan, Gilead, Genentech, Intercept, and Sanofi-Aventis. T.P. is a consultant for and owns 15% of Biopredictive, a company that markets FibroTest and SteatoTest. These conflicts of interest have been disclosed to study participants.
enthalten in:
Hepatology
| 2010
von
Chapman, R.
|
Fevery, J.
|
Kalloo, A.
| +4
Wird geladen...
3
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonrespondersThe METRO study (VX03-497-205) is registered with ClinicalTrials.gov (NCT00088504). The METRO study was funded by Vertex Pharmaceuticals Inc., the developer of MMPD. The authors had full access to the study data, and the corresponding author had final responsibility to prepare and submit the manuscript for publication.Potential conflict of interest: Dr. Lee reports receiving consulting fees from AstraZeneca Pharmaceuticals, Eli Lilly and Co., and Fibrogen Inc., and grant support from Bristol-Myers Squibb, Roche, Schering-Plough Corp. Siemens, and Vertex Pharmaceuticals; Dr. Lawitz, grant support from Abbott Laboratories Anadys Pharmaceuticals, Inc., Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline GlobeImmune Inc., Human Genome Sciences, Idenix Pharmaceuticals, Idera Pharmaceuticals Intarcia Therapeutics, Inc., Medarex Inc., Merck & Co., Inc., Novartis, Roche, sanofi-aventi
enthalten in:
Hepatology
| 2009
von
Itsui, Y.
|
Sakamoto, N.
|
Kakinuma, S.
| +13
Wird geladen...
4
Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis CThis study is registered on ClinicalTrials.gov (identifier NCT00115908; URL XML-LINK="SIMPLE" HREF="http: clinicaltrials.gov-ct2-show-NCT00115908?term=human- +genome+sciences&rank=2">http: clinicaltrials.gov-ct2-show- -NCT00115908?term=human+genome+sciences&rank=2&- #41;Potential conflict of interest: Dr. McHutchison is a consultant for and received grants from Anadys, Colsy Pharmaceutical Group, First Circle Medical, GlaxoSmithKline, Human Genome Sciences, Idenix Pharmaceuticals, Intarcia, Novartis, Pharmasset, Pfizer, Roche, Schering-Plough, Valeant Pharmaceuticals, Vertex Pharmaceuticals, and Wyeth. He received grants from Globe Immune, Medtronics, Salix Pharmaceuticals, and Sanofi-Aventis. He is also a consultant for Biolex, Epiphany Biosciences, InterMune Pharmaceuticals, National Genetics Institute, Peregrine, and United Therapeutics. Drs. Subramanian, Cronin and Pulkstenis own stock in Human Genome Sciences, Inc. Dr. Kaita is a consultant for, is on the speakers' bureau of, and received gran
enthalten in:
Hepatology
| 2008
von
Zeuzem, S.
|
Yoshida, E.
|
Benhamou, Y.
| +11
Wird geladen...
1
[1]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Medienart: Gedruckte Aufsätze
Filter aufheben
Zeitschrift: Hepatology
Medienart
4
Aufsätze
Gedruckte Aufsätze
Zeitschriftentitel
Hepatology
Erscheinungszeitraum
2
2010-2019
2
2000-2009
Erscheinungsjahr(e)
Von:
Bis:
Haven't found what you're looking for?
Wird geladen...